AprilBio에이프릴바이오
397030 · KOSDAQ · ₩397030 · 에이프릴바이오
₩12,340▼ ₩60 (0.48%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — |
| Operating margin | −1,324.1% | −334.4% | 61.3% | — | −5,737.2% |
| Net margin | −1,242.5% | −447.9% | 72.7% | — | −4,479.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue growth | −66.6% | −92.1% | — | −100.0% | — |
| Operating income growth | −32.2% | −143.1% | +226.0% | −16.7% | — |
| Net income growth | +7.4% | −148.6% | +241.6% | −57.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Return on equity | −9.3% | −10.4% | 26.9% | −22.3% | −13.0% |
| Return on assets | −9.2% | −9.9% | 22.3% | −18.7% | −12.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Liabilities to equity | 1.5% | 0.8% | 9.5% | 38.0% | 2.8% |
| Net debt to equity | −82.5% | −96.3% | −100.8% | −100.6% | −8.4% |
| Current ratio | 6,769.6% | 17,490.4% | 1,139.2% | 306.9% | 3,880.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: AprilBio / 에이프릴바이오 / 397030 / KRX:397030
Source: KRX statistical information